February 22, 2013 at 09:26 AM EST
FDA Confirms Approval of Kadcyla for Breast Cancer
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla™ ^ (ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin^® (trastuzumab) and a taxane chemotherapy. Kadcyla is the fourth medicine from Genentech
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here